15.59
1.23%
+0.19
After Hours:
15.48
-0.11
-0.71%
Viridian Therapeutics Inc stock is currently priced at $15.59, with a 24-hour trading volume of 564.91K.
It has seen a +1.23% increased in the last 24 hours and a -4.47% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $15.30 pivot point. If it approaches the $15.60 resistance level, significant changes may occur.
Previous Close:
$15.40
Open:
$15.49
24h Volume:
564.91K
Market Cap:
$994.99M
Revenue:
$314.00K
Net Income/Loss:
$-237.73M
P/E Ratio:
-3.2012
EPS:
-4.87
Net Cash Flow:
$-185.07M
1W Performance:
+14.63%
1M Performance:
-4.47%
6M Performance:
+4.63%
1Y Performance:
-40.72%
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
720 643 5200
Address
6200 Lookout Road, Boulder
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-14-23 | Initiated | BTIG Research | Buy |
Jun-14-23 | Resumed | Credit Suisse | Outperform |
May-30-23 | Initiated | RBC Capital Mkts | Outperform |
Apr-17-23 | Initiated | Wells Fargo | Overweight |
Mar-30-23 | Initiated | Stifel | Buy |
Dec-19-22 | Initiated | Cowen | Outperform |
Dec-19-22 | Initiated | Needham | Buy |
Dec-16-22 | Initiated | Credit Suisse | Outperform |
Dec-01-22 | Initiated | H.C. Wainwright | Buy |
Jun-23-22 | Initiated | B. Riley Securities | Buy |
Nov-18-21 | Initiated | SVB Leerink | Outperform |
Oct-12-21 | Initiated | Evercore ISI | Outperform |
Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
Unveiling 4 Analyst Insights On Viridian Therapeutics
Benzinga
How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81%
Zacks Investment Research
Navigating 6 Analyst Ratings For Viridian Therapeutics
Benzinga
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Janux Therapeutics, Inc. (JANX) Moves 5.6% Higher: Will This Strength Last?
Zacks Investment Research
ZimVie Agrees To Sell Its Spine Business, Joins United States Steel, PGT Innovations And Other Big Stocks Moving Higher On Monday
Benzinga
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Viridian Therapeutics Inc (VRDN) Revenue 2024
VRDN reported a revenue (TTM) of $314.00 thousand for the quarter ending December 31, 2023, a -82.28% decline year-over-year.
Viridian Therapeutics Inc (VRDN) Net Income 2024
VRDN net income (TTM) was -$237.73 million for the quarter ending December 31, 2023, a -83.05% decrease year-over-year.
Viridian Therapeutics Inc (VRDN) Cash Flow 2024
VRDN recorded a free cash flow (TTM) of -$185.07 million for the quarter ending December 31, 2023, a -95.56% decrease year-over-year.
Viridian Therapeutics Inc (VRDN) Earnings per Share 2024
VRDN earnings per share (TTM) was -$5.32 for the quarter ending December 31, 2023, a -32.01% decline year-over-year.
About Viridian Therapeutics Inc
Viridian Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Cap:
|
Volume (24h):